Description
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer
OncQuer(TM) CMML panel
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer
TAT:
Specimen Type:
Genomics Panel Test
Other Tests
-
264%
OncQuer TM Germline Mutation Panel by NGS
Identification of gene mutations that increase risk of cancer or has therapeutic implications in an affected individual
OncQuer TM Germline Mutation Panel by NGS
Identification of gene mutations that increase risk of cancer or has therapeutic implications in an affected individual
-
222%
BRCA1 BRCA2 TP53 Gene Testing (Blood) By NGS
Panel of BRCA1&2 Genes
-
264%
OncQuer TM Scout LB EGFR Sensitivity Test
Identification gene mutations leading to sensitivity to EGFR therapy
OncQuer TM Scout LB EGFR Sensitivity Test
Identification gene mutations leading to sensitivity to EGFR therapy
-
264%
OncQuer TM Scout LB EGFR Resistance Test
Identification gene mutations leading to resistance to EGFR therapy
OncQuer TM Scout LB EGFR Resistance Test
Identification gene mutations leading to resistance to EGFR therapy
Reviews
There are no reviews yet.